Raltegravir in vitro effect on bilirubin binding

Pediatric Infectious Disease Journal

Volumn 32, Issue 9, 2013, Pages 978-980

  Clarke, Diana E ^a   Wong, Ronal D I ^b   Wenning, Larissa ^c   Stevenson, David K ^b   Mirochnick, Mark ^a  

^a BOSTON MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bilirubin binding; Neonate; Raltegravir

Indexed keywords

ALBUMIN; BILIRUBIN; HORSERADISH PEROXIDASE; RALTEGRAVIR; SULFAFURAZOLE;

ARTICLE; BILIRUBIN BINDING; BINDING COMPETITION; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; NEWBORN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL;

ANTI-HIV AGENTS; BILIRUBIN; HUMANS; INFANT, NEWBORN; PROTEIN BINDING; PYRROLIDINONES; SERUM; SERUM ALBUMIN;

EID: 85047687151     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31829044a8     Document Type: Article

References (14)

1. Mirochnick M, Best BM, Clarke DF. Antiretroviral pharmacology: special issues regarding pregnant women and neonates. Clin Perinatol. 2010;37:907-927, xi.
2. Andersen DH, Blanc WA, Crozier DN, et al. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics. 1956;18:614-625.
3. Harris RC, Lucey JF, Maclean JR. Kernicterus in premature infants associated with low concentrations of bilirubin in the plasma. Pediatrics. 1958;21:875-884.
4. Jacobsen J, Wennberg RE Determination of unbound bilirubin in the serum of newborns. Clin Chem. 1974;20:783.
5. Ahlfors CE. Effect of ibuprofen on bilirubin-albumin binding. J Pediatr. 2004;144:386-388.
6. Rasmussen LF, Ahlfors CE, Wennberg RP The effect of paraben preservatives on albumin binding of bilirubin. J Pediatr. 1976;89:475-478.
7. Ahlfors CE, Marshall GD, Wolcott DK, et al. Measurement of unbound bilirubin by the peroxidase test using Zone Fluidics. Clin Chim Acta. 2006;365:78-85.
8. Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta. 1971;31:87-96.
9. Burger DM. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies. Expert Opin Drug Metab Toxicol. 2010;6:1151-1160.
10. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43:509-515.
11. Nachman S, Acosta EP, Zheng N, et al. Interim results from IMPAACT P1066: RAL chewable tablet formulation for 2 to 5 year olds. Paper presented at: The 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, MA. Abstract 715.
12. Kawade N, Onishi S. The prenatal and postnatal development of UDP-glucuronyltransferase activity towards bilirubin and the effect of premature birth on this activity in the human liver. Biochem J. 1981;196:257-260.
13. Allegaert K, Vanhaesebrouck S, Verbesselt R, et al. In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age. Ther Drug Monit. 2009;31:411-415.
14. Wenning LA, Petry AS, Kost JT, et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther. 2009;85:623-627.